Fadrozole
(Synonyms: 法倔唑; CGS 16949A free base; (Rac)-FAD286) 目录号 : GC19151
Fadrozole (CGS 16949A)是一种选择性非甾体芳香酶抑制剂，IC50 值为4.5μM。
Cas No.:102676-47-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Fadrozole (CGS 16949A) is a selective, non-steroidal aromatase inhibitor with an IC50 value of 4.5μM[1]. Fadrozole has been investigated as a treatment of hormone-responsive breast cancer (estrogen sensitive)[1]. Aromatase is an enzyme that plays a vital role in converting androgens (like testosterone) into estrogens (like estradiol). Fadrozole can be used to block aromatase and reduces the level of estrogens[2].
In vitro, prolactin-positive cells were extracted from male Wistar rats. By treating prolactin-positive cells with 1μM Fadrozole alone for 1, 3, 6 or 12 hours respectively, no statistically significant variations in the cellular area and proliferation rates were observed due to absent testosterone and minimal synthesized estradiol[3]. When treating cells with 1μM Fadrozole and 1μM testosterone, significantly decreased of the size of prolactin-positive cells as well as reduced percentage of proliferation rates were obtained from 3 to 12 hours treatment[3].
In vivo, Fadrozole (300μg/day) was inplantated with mini-osmotic pumps on day 14 of pregnancy Sprague–Dawley rats to reduce the level of estradiol-17 (E2)[4]. Fadrozole (1200μg; 4 days) resulted in a significant reduced E2 concentration and high level of androstenedione and testosterone in pregnant rats[4]. Fadrozole (1800μg; 6 days) led to a fourfold increased intrauterine pressure with significant smaller uterine tissue framework in pregnant rats[2,4]. Fadrozole caused fetal abnormalities in pregnant rats, where 20% of fetuses had head injuries while their weight did not differ from normal fetuses[4].
References:
[1] Browne LJ, Gude C, Rodriguez H, Steele RE, Bhatnager A. Fadrozole hydrochloride: a potent, selective, nonsteroidal inhibitor of aromatase for the treatment of estrogen-dependent disease. Journal of medicinal chemistry. 1991 Feb;34(2):725-36.
[2] Tiboni GM, Ponzano A. Fetal safety profile of aromatase inhibitors: Animal data. Reproductive Toxicology. 2016 Dec 1;66:84-92.
[3] Patil CN, Li W, Wang X. Local transformations of androgens into estradiol by aromatase P450 are involved in the regulation of prolactin and the proliferation of pituitary prolactin-positive cells. J Endocrinol. 2014;222(2):201–12. doi:10.1530/JOE-13-0579.
[4] Tamada H, Shimizu Y, Inaba T, Kawate N, Sawada T. The effects of the aromatase inhibitor fadrozole hydrochloride on fetuses and uteri in late pregnant rats. Journal of endocrinology. 2004 Feb 1;180(2):337-46.
Fadrozole (CGS 16949A)是一种选择性非甾体芳香酶抑制剂，IC50 值为4.5μM[1]。Fadrozole已被研究用于治疗激素反应性乳腺癌（雌激素敏感）[1]。芳香酶在将雄激素（如睾酮）转化为雌激素（如雌二醇）中有着关键的作用。Fadrozole可用于阻断芳香酶并降低雌激素水平[2]。
在体外研究中，从Wistar雄性大鼠中提取催乳素阳性细胞，单独使用1μM的Fadrozole分别孵育1，3 ，6和12小时。由于细胞缺乏睾酮和极少合成的雌二醇，未观察到显著的细胞面积和增值率变化[3]。当合并使用1μM的Fadrozole和1μM的睾酮时，在3至12小时细胞孵育期间，催乳素阳性细胞的细胞大小显著减小并伴有细胞增值率的下降[3]。
在体内研究中，在Sprague–Dawley妊娠大鼠第14天时利用微型渗透泵将Fadrozole（300μg/day）注入体内以降低雌二醇-17（E2）[4]。Fadrozole（1200μg； 4天）导致妊娠大E2的浓度显著降低，且雄烯二酮和睾酮水平升高[4]。Fadrozole（1800μg；6天）导致妊娠大鼠子宫内压增加四倍，子宫组织框架变小[2，4]。Fadrozole导致妊娠大鼠胎儿畸形，其中20% 的小鼠胎儿头部有损伤，但其体重与正常小鼠胎儿没有差异[4]。
| Cell experiment [1]: | |
Cell lines | Prolactin-positive cells |
Preparation Method | Male Wistar rats (175–200g) were killed to extract prolactin-positive cells. Prolactin-positive cells were seeded on 60 culture chamber slides at a final concertation of 2.5×105/ml cells and incubated with Dulbecco’s modified Eagle’s medium (DMEM) for 7 days. On day 4, medium was changed by fresh DMEM. On day 7, cell cultures were treated with 1μM testosterone, 1μM Fadrozole and incubated for 1, 3, 6 or 12 hours (5 chambers per treatment). After treatment, the chambers were washed with Dubelcco’s sterile PBS, and cells were fixed in Somogy’s solution for 1 hour, followed by rinsing in PBS. |
Reaction Conditions | 1μM testosterone, 1μM Fadrozole; 1, 3, 6 or 12 hours |
Applications | Fadrozole alone did not affect prolactin-positive cells. Combination of Fadrozole and testosterone significantly decreases prolactin-positive cells sizes and proliferation rates. |
| Animal experiment [2]: | |
Animal models | Sprague–Dawley female rats |
Preparation Method | Female rats (180-300g) were mated when 60-120 days old. On day 14 of pregnancy rats were divided into three groups. Group 1 (Fad) rats were implanted s.c. with mini-osmotic pumps containing Fadrozole (300μg/day). Group 2 (control) rats were implanted s.c. with mini-osmotic pumps containing saline. Group 3 (Fad+E2) rats were implanted s.c. with mini-osmotic pumps containing Fadrozole (300μg/day) and estradiol-17 (E2) (0.2μg/day, E2 was dissolved in 0.2ml sesame oil). On day 17 of pregnancy, blood samples were collected from the abdominal aorta of rats in all 3 groups. On day 20 of pregnancy, all 3 groups rats underwent laparotomy under ether anesthesia. |
Dosage form | Fadrozole: 300μg/day for 6 days; estradiol-17: 0.2μg/day for 6 days |
Applications | Fadrozole treatment significantly reduced E2 concentration, and led to a fourfold increased intrauterine pressure with smaller uterine tissue framework in pregnant rats. Fadrozole caused fetal abnormalities in pregnant rats, but their weight did not differ from normal fetuses. The combination treatment of Fadrozole and E2 had similar effect as control groups, indicating that exogenously supplied E2 could compensate for the loss of endogenous E2. |
References: | |
| Cas No. | 102676-47-1 | SDF | |
| 别名 | 法倔唑; CGS 16949A free base; (Rac)-FAD286 | ||
| Canonical SMILES | N#CC1=CC=C(C2CCCC3=CN=CN23)C=C1 | ||
| 分子式 | C14H13N3 | 分子量 | 223.27 |
| 溶解度 | DMSO : ≥ 100 mg/mL (447.89 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 4.4789 mL | 22.3944 mL | 44.7888 mL |
| 5 mM | 0.8958 mL | 4.4789 mL | 8.9578 mL |
| 10 mM | 0.4479 mL | 2.2394 mL | 4.4789 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet